Skip to content
10-K

Annual Report

Applied Therapeutics, Inc.

0000950170-25-053840

← back to feed
Filed
Apr 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Apr 11, 2025 141.58M sh
Shares Diluted FY 2024 · Dec 31, 2024 139.53M sh
Shares Diluted FY 2024 · Dec 31, 2023 84.24M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$84.31M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$55.17M
Cash And Equivalents FY 2024 · Dec 31, 2024 $79.4M
Cash And Equivalents FY 2024 · Dec 31, 2023 $49.9M
Stockholders Equity FY 2024 · Dec 31, 2024 $57.01M
Stockholders Equity FY 2024 · Dec 31, 2023 −$17.15M
Stockholders Equity FY 2024 · Dec 31, 2022 $4.06M
Current Liabilities FY 2024 · Dec 31, 2024 $27.3M
Current Liabilities FY 2024 · Dec 31, 2023 $71.18M
Total Liabilities FY 2024 · Dec 31, 2024 $29.69M
Total Liabilities FY 2024 · Dec 31, 2023 $71.98M
Current Assets FY 2024 · Dec 31, 2024 $83.65M
Current Assets FY 2024 · Dec 31, 2023 $54.39M
Total Assets FY 2024 · Dec 31, 2024 $86.69M
Total Assets FY 2024 · Dec 31, 2023 $54.83M
Eps Diluted FY 2024 · Dec 31, 2024 −$0.76
Eps Diluted FY 2024 · Dec 31, 2023 −$1.42
Eps Basic FY 2024 · Dec 31, 2024 −$0.76
Eps Basic FY 2024 · Dec 31, 2023 −$1.42
Sga Expense FY 2024 · Dec 31, 2024 $56.01M
Sga Expense FY 2024 · Dec 31, 2023 $20.62M
Rd Expense FY 2024 · Dec 31, 2024 $48.74M
Rd Expense FY 2024 · Dec 31, 2023 $53.91M
Net Income FY 2024 · Dec 31, 2024 −$105.62M
Net Income FY 2024 · Dec 31, 2023 −$119.76M
Operating Income FY 2024 · Dec 31, 2024 −$104.3M
Operating Income FY 2024 · Dec 31, 2023 −$64.54M
Revenue FY 2024 · Dec 31, 2024 $455K
Revenue FY 2024 · Dec 31, 2023 $9.99M